Mr. William Mann, also known as Bill, MBA, Ph.D., serves as Chief Executive Officer and President of Helsinn Therapeutics (U.S.), Inc. Mr. Mann served as Vice president of Corporate Development at Helsinn Therapeutics (U.S.), Inc. since August 25, 2006. Mr. Mann served as Executive Director of business development and scientific affairs of Helsinn Therapeutics (U.S.), Inc. (Alternate name: Sapphire Therapeutics, Inc.) until August 2006. He joined Sapphire Therapeutics from the Global Business Development and Licensing group at Novartis, where he was responsible for worldwide in-licensing for the Cardiovascular and Metabolism Business Franchise. He was also responsible for monitoring the pipelines of East Coast U.S. and Canadian biotech companies for in-licensing opportunities for all therapeutic areas at Novartis. He also served as Research Lab Director of Novartis and later led a multidisciplinary drug discovery project team. He served as Discovery Research Delegate and Founding member of Novartis multidisciplinary development team. He serves as a Director of Helsinn Therapeutics (U.S.), Inc. He served as Director of Novartis. He earned a PhD in Biochemistry from the University of Aberdeen, Scotland, performed postdoctoral studies at the Rockefeller University in New York City and earned an MBA from the Rutgers Graduate School of Management in Newark.

 Business